Gene therapy for rheumatoid arthritis

Elvire Gouze, Steven C. Ghivizzani, Glyn D. Palmer, Jean Noel Gouze, Paul D. Robbins, Christopher H Evans

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Rheumatoid arthritis (RA) is a disabling, painful disorder affecting 1% of the worlds population. Although the aetiology of RA remains unknown, recent advances in understanding its pathophysiology have led to the characterisation of several proteins whose activities may be anti-arthritic. Clinical application of such proteins has greatly improved the treatment of RA, but the disease remains incurable and difficult to manage in a substantial number of patients. Thus, there are continued efforts to develop new therapeutic strategies. Because RA is a chronic condition, effective treatment will probably require the presence of therapeutic agents for extended periods of time. In the case of proteins, this is problematic. Gene therapy may offer a solution to this problem. Experimental studies have confirmed the feasibility, efficacy and safety of gene therapy for the treatment of animal models of arthritis. Several different approaches have shown promise in this regard, including gene transfer to the synovial lining cells of individual joints and the systemic delivery of genes to extra-articular locations. One unexpected finding has been the contralateral effect in which gene delivery to one joint of an animal with polyarticular disease leads to improvement of multiple joints. Investigation of this phenomenon has led to interest in cell trafficking and the genetic modification of antigen-presenting cells (APC). The first Phase I clinical trial tested the feasibility and safety of ex vivo gene transfer to the synovial lining of human joints. This clinical trial has been successfully completed and two other Phase I trials are in progress. A Phase II study is now being planned to investigate the efficacy of gene transfer to the joints of patients with early stage RA.

Original languageEnglish (US)
Pages (from-to)971-978
Number of pages8
JournalExpert Opinion on Biological Therapy
Volume1
Issue number6
DOIs
StatePublished - Nov 1 2001
Externally publishedYes

Fingerprint

Gene transfer
Gene therapy
Genetic Therapy
Rheumatoid Arthritis
Joints
Linings
Animals
Genes
Proteins
Arthritis
Therapeutics
Safety
Clinical Trials, Phase I
Antigen-Presenting Cells
Animal Models
Clinical Trials
Population

Keywords

  • contralateral effect
  • gene therapy
  • IL-1 receptor antagonist
  • rheumatoid arthritis

ASJC Scopus subject areas

  • Pharmacology
  • Clinical Biochemistry
  • Drug Discovery

Cite this

Gouze, E., Ghivizzani, S. C., Palmer, G. D., Gouze, J. N., Robbins, P. D., & Evans, C. H. (2001). Gene therapy for rheumatoid arthritis. Expert Opinion on Biological Therapy, 1(6), 971-978. https://doi.org/10.1517/14712598.1.6.971

Gene therapy for rheumatoid arthritis. / Gouze, Elvire; Ghivizzani, Steven C.; Palmer, Glyn D.; Gouze, Jean Noel; Robbins, Paul D.; Evans, Christopher H.

In: Expert Opinion on Biological Therapy, Vol. 1, No. 6, 01.11.2001, p. 971-978.

Research output: Contribution to journalArticle

Gouze, E, Ghivizzani, SC, Palmer, GD, Gouze, JN, Robbins, PD & Evans, CH 2001, 'Gene therapy for rheumatoid arthritis', Expert Opinion on Biological Therapy, vol. 1, no. 6, pp. 971-978. https://doi.org/10.1517/14712598.1.6.971
Gouze E, Ghivizzani SC, Palmer GD, Gouze JN, Robbins PD, Evans CH. Gene therapy for rheumatoid arthritis. Expert Opinion on Biological Therapy. 2001 Nov 1;1(6):971-978. https://doi.org/10.1517/14712598.1.6.971
Gouze, Elvire ; Ghivizzani, Steven C. ; Palmer, Glyn D. ; Gouze, Jean Noel ; Robbins, Paul D. ; Evans, Christopher H. / Gene therapy for rheumatoid arthritis. In: Expert Opinion on Biological Therapy. 2001 ; Vol. 1, No. 6. pp. 971-978.
@article{48bebc53876b45148111b28c79b4204c,
title = "Gene therapy for rheumatoid arthritis",
abstract = "Rheumatoid arthritis (RA) is a disabling, painful disorder affecting 1{\%} of the worlds population. Although the aetiology of RA remains unknown, recent advances in understanding its pathophysiology have led to the characterisation of several proteins whose activities may be anti-arthritic. Clinical application of such proteins has greatly improved the treatment of RA, but the disease remains incurable and difficult to manage in a substantial number of patients. Thus, there are continued efforts to develop new therapeutic strategies. Because RA is a chronic condition, effective treatment will probably require the presence of therapeutic agents for extended periods of time. In the case of proteins, this is problematic. Gene therapy may offer a solution to this problem. Experimental studies have confirmed the feasibility, efficacy and safety of gene therapy for the treatment of animal models of arthritis. Several different approaches have shown promise in this regard, including gene transfer to the synovial lining cells of individual joints and the systemic delivery of genes to extra-articular locations. One unexpected finding has been the contralateral effect in which gene delivery to one joint of an animal with polyarticular disease leads to improvement of multiple joints. Investigation of this phenomenon has led to interest in cell trafficking and the genetic modification of antigen-presenting cells (APC). The first Phase I clinical trial tested the feasibility and safety of ex vivo gene transfer to the synovial lining of human joints. This clinical trial has been successfully completed and two other Phase I trials are in progress. A Phase II study is now being planned to investigate the efficacy of gene transfer to the joints of patients with early stage RA.",
keywords = "contralateral effect, gene therapy, IL-1 receptor antagonist, rheumatoid arthritis",
author = "Elvire Gouze and Ghivizzani, {Steven C.} and Palmer, {Glyn D.} and Gouze, {Jean Noel} and Robbins, {Paul D.} and Evans, {Christopher H}",
year = "2001",
month = "11",
day = "1",
doi = "10.1517/14712598.1.6.971",
language = "English (US)",
volume = "1",
pages = "971--978",
journal = "Expert Opinion on Biological Therapy",
issn = "1471-2598",
publisher = "Informa Healthcare",
number = "6",

}

TY - JOUR

T1 - Gene therapy for rheumatoid arthritis

AU - Gouze, Elvire

AU - Ghivizzani, Steven C.

AU - Palmer, Glyn D.

AU - Gouze, Jean Noel

AU - Robbins, Paul D.

AU - Evans, Christopher H

PY - 2001/11/1

Y1 - 2001/11/1

N2 - Rheumatoid arthritis (RA) is a disabling, painful disorder affecting 1% of the worlds population. Although the aetiology of RA remains unknown, recent advances in understanding its pathophysiology have led to the characterisation of several proteins whose activities may be anti-arthritic. Clinical application of such proteins has greatly improved the treatment of RA, but the disease remains incurable and difficult to manage in a substantial number of patients. Thus, there are continued efforts to develop new therapeutic strategies. Because RA is a chronic condition, effective treatment will probably require the presence of therapeutic agents for extended periods of time. In the case of proteins, this is problematic. Gene therapy may offer a solution to this problem. Experimental studies have confirmed the feasibility, efficacy and safety of gene therapy for the treatment of animal models of arthritis. Several different approaches have shown promise in this regard, including gene transfer to the synovial lining cells of individual joints and the systemic delivery of genes to extra-articular locations. One unexpected finding has been the contralateral effect in which gene delivery to one joint of an animal with polyarticular disease leads to improvement of multiple joints. Investigation of this phenomenon has led to interest in cell trafficking and the genetic modification of antigen-presenting cells (APC). The first Phase I clinical trial tested the feasibility and safety of ex vivo gene transfer to the synovial lining of human joints. This clinical trial has been successfully completed and two other Phase I trials are in progress. A Phase II study is now being planned to investigate the efficacy of gene transfer to the joints of patients with early stage RA.

AB - Rheumatoid arthritis (RA) is a disabling, painful disorder affecting 1% of the worlds population. Although the aetiology of RA remains unknown, recent advances in understanding its pathophysiology have led to the characterisation of several proteins whose activities may be anti-arthritic. Clinical application of such proteins has greatly improved the treatment of RA, but the disease remains incurable and difficult to manage in a substantial number of patients. Thus, there are continued efforts to develop new therapeutic strategies. Because RA is a chronic condition, effective treatment will probably require the presence of therapeutic agents for extended periods of time. In the case of proteins, this is problematic. Gene therapy may offer a solution to this problem. Experimental studies have confirmed the feasibility, efficacy and safety of gene therapy for the treatment of animal models of arthritis. Several different approaches have shown promise in this regard, including gene transfer to the synovial lining cells of individual joints and the systemic delivery of genes to extra-articular locations. One unexpected finding has been the contralateral effect in which gene delivery to one joint of an animal with polyarticular disease leads to improvement of multiple joints. Investigation of this phenomenon has led to interest in cell trafficking and the genetic modification of antigen-presenting cells (APC). The first Phase I clinical trial tested the feasibility and safety of ex vivo gene transfer to the synovial lining of human joints. This clinical trial has been successfully completed and two other Phase I trials are in progress. A Phase II study is now being planned to investigate the efficacy of gene transfer to the joints of patients with early stage RA.

KW - contralateral effect

KW - gene therapy

KW - IL-1 receptor antagonist

KW - rheumatoid arthritis

UR - http://www.scopus.com/inward/record.url?scp=0035516173&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035516173&partnerID=8YFLogxK

U2 - 10.1517/14712598.1.6.971

DO - 10.1517/14712598.1.6.971

M3 - Article

C2 - 11728228

AN - SCOPUS:0035516173

VL - 1

SP - 971

EP - 978

JO - Expert Opinion on Biological Therapy

JF - Expert Opinion on Biological Therapy

SN - 1471-2598

IS - 6

ER -